live Related news:
Amgen starts two critical late-stage trials for weight loss drug MariTide - Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup - Ozempic competitor in the works at Amgen reaches late-stage clinical trials - Amgen just got one step closer to bringing its Ozempic competitor to market - Amgen injects $200m in Hyd with new tech centre - Healthy Returns: Wall Street mulls over Amgen's weight loss drug data - Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau - Stocks making the biggest moves premarket: Amgen, Best Buy, Abercrombie & Fitch, Stellantis and more - Amgen says its Ozempic competitor helped patients lose 20% of their weight. Wall Street isn't impressed - Amgen says no concerns around weight loss drug's bone density data after stock falls

Amgen

1 day ago
bookmarkBookmark

Amgen is a company. It is located in Thousand Oaks, the United States and was founded in 1980. The company is part of the Health Care sector, specifically in the Pharmaceuticals industry.

Key facts

Classified as: organization

link Website
link LinkedIn: 919K followers
link X (Twitter): 124K followers

Business

Amgen is one of the companies in the United States, companies in Pharmaceuticals, companies in Health Care and 3,550,070 companies in our database.

  • Assets: 61.2B $
  • Debt: 36.9B $
  • Employees: 24,200 people
  • Free cash flow: 7.4B $
  • Market cap: 138B $
  • Profits: 5.9B $
  • Revenues: 26.3B $

dataset Stocks from Amgen:

Talking Points

  • AmgenA Worldwide Pioneer in Biotechnology
  • Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.
  • Patients. They're why we develop and manufacture innovative human therapeutics to treat serious diseases. Community Guidelines: https:
  • t.co
  • YlIOJSHFPG
  • #WeareBiotech | Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology
  • hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar
  • Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Learn more about talking points

In literature

There is no book written about Amgen in the database.

Related

Connected or similar to Amgen:

Details

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.